Proton pump inhibitors (PPI) are used to reduce the clinical manifestations of gastrointestinal reflux disease, but there is an increased risk of complications from Crohn’s disease and ulcerative colitis (IBD) associated with the use of PPI. PPI may affect the GI and oral microbiota as well as influence bone metabolism. In addition, IBD has been positively associated with an inflammatory host response following bacterial infection characteristic of peri-implantitis. Consequently, we hypothesized that the severity of bone loss around dental implants might be related to the use of PPI.